scholarly journals Association of serum uric acid concentration with components of pediatric metabolic syndrome: A systematic review and meta-analysis

2020 ◽  
Vol 25 (1) ◽  
pp. 43
Author(s):  
SeyedeShahrbanoo Daniali ◽  
Roya Kelishadi ◽  
Parvin Goli ◽  
Roya Riahi ◽  
Mohammadali Pourmirzaei
2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Anna Masajtis-Zagajewska ◽  
Jacek Majer ◽  
Michał Nowicki

Introduction. Excessive intake of fructose increases serum uric acid concentration. Hyperuricemia induces a negative effect on atherosclerosis and inflammation. Hyperuricemia is common in patients with arterial hypertension. Several antihypertensive drugs including diuretics increase serum uric acid concentration. In contrast, the angiotensin II receptor antagonist (ARB) losartan was found to lower serum uric acid though it may increase renal excretion while other ARBs showed mostly a neutral effect. In this study, effects of two AT1 receptor antagonists losartan and eprosartan on serum uric acid changes induced by oral fructose load were directly compared. Methods. The randomized, crossover, head-to-head comparative study comprised 16 ambulatory patients (mean age 64.5 ± 9.8 years). The patients fulfilled AHA/NHLBI 2005 criteria of metabolic syndrome. A daily single morning dose of each study drug (50 mg of losartan or 600 mg of eprosartan) was given during two 3-month periods in a random order separated by 2-week washout time. The oral fructose tolerance test (OFTT) was performed at baseline and after each two 3-onth treatment periods. Before and during OFTT, urine excretion of uric acid and creatinine was assessed in the first morning portion of urine. Blood samples for the measurement of serum uric acid and lipids were taken at baseline and 30, 60, and 120 minutes after oral intake of 75 g of fructose. Results. After 3-month treatment with eprosartan and losartan, both systolic and diastolic blood pressure decreased significantly and to a similar extent. After the treatment, serum uric acid and its baseline and postfructose urine excretion were unchanged. No significant changes of plasma lipids before and after OFTT were observed throughout the study. Conclusions. The study showed that in patients with hypertension and metabolic syndrome, both losartan and eprosartan have a neutral effect on fasting and postfructose load serum uric acid concentration and its urinary excretion. This trial is registered with NCT04954560.


2005 ◽  
Vol 69 (8) ◽  
pp. 928-933 ◽  
Author(s):  
Tae Woo Yoo ◽  
Ki Chul Sung ◽  
Hun Sub Shin ◽  
Byung Jin Kim ◽  
Bum Soo Kim ◽  
...  

2018 ◽  
Vol 12 (3) ◽  
pp. 325-331 ◽  
Author(s):  
Leonardo M. Porchia ◽  
M. Elba Gonzalez-Mejia ◽  
Enrique Torres-Rasgado ◽  
Guadalupe Ruiz-Vivanco ◽  
Ricardo Pérez-Fuentes

2013 ◽  
pp. 103-106
Author(s):  
Giovanni Gulli ◽  
Luigi De Filippis

BACKGROUND Febuxostat is a non-purine selective inhibitor of xanthine oxidase whose therapeutic effect is decreasing the serum uric acid concentration. Febuxostat has a marketing authorisation for the treatment of chronic hyperuricaemia in conditions where urate/uric acid deposition has already occurred. The recommended dose of febuxostat is 80 mg once daily. If the person’s serum uric acid concentration is above 6 mg/dL after 2-4 weeks, febuxostat 120 mg once daily may be considered. The most common side effects associated with febuxostat are diarrhoea, nausea, headache, liver function test abnormalities and rash. The evidence in support of the clinical effectiveness of febuxostat in comparison with allopurinol is not strong. DISCUSSION A meta-analysis showed that although the urate-lowering efficacy of febuxostat was statistically significantly higher than fixed-dose allopurinol (300 mg/day), a higher proportion of patients receiving febuxostat needed treatment for gout flares compared with those receiving fixed-dose allopurinol. For the febuxostat 80 mg/day group this difference was not statistically significant (p > 0.18), but for the 120 mg/day febuxostat group it was. Moreover, guidelines recommend dose titration for allopurinol according to therapeutic targets. It is possible that dose-titrated allopurinol may be more effective than fixed-dose allopurinol. CONCLUSIONS Febuxostat is a plausible improvement on current second-line options. These options are considered where allopurinol is not appropriate, e.g. because of chronic kidney disease, intolerance or lack of response.


Sign in / Sign up

Export Citation Format

Share Document